Genmab A/S shares rise 4.09% intraday after positive Phase 2 trial results for epcoritamab.

Genmab A/S rose 4.09% intraday, with the company announcing updated results from the Phase 2 EPCORE® NHL-6 trial. The trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in an outpatient setting. The study showed that 92% of patients received the first full dose of epcoritamab monotherapy in an outpatient setting, with an overall response rate of 64.3% and a complete response rate of 47.6%. The adverse event profile and efficacy were consistent with previously reported studies.